Inform has been approved for the prediction of breast cancer. It is a gene-based test which identifies the presence or absence of increased copies of the HER-2/neu gene, a gene known to have an increased presence in a particularly aggressive form of breast cancer.
In studies with early breast cancer patients, 69% of the women who tested positive for the HER-2/neu gene survived five years after surgery compared with 97% of patients with negative test results.
The Inform HER-2/neu breast cancer test drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.